Podiatrists in Kennebunk, ME Accepting Medicare
5 Podiatrists found. Showing 1 - 5
 Foot & Ankle Center Of Southern Maine Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 75 Portland Rd, Kennebunk, ME 04043 Phone: 207-985-9888 Fax: 207-985-3488 |
Sally Ann Warren Dpm Pllc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 75 Portland Rd, Kennebunk, ME 04043 Phone: 207-985-9888 Fax: 207-985-3488 |
Kenneth D Warren Dpm Pllc Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 2 Berry Ct, Kennebunk, ME 04043 Phone: 207-985-9888 Fax: 207-985-3488 |
 Leon P Hickey, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 7 Shape Dr, Kennebunk, ME 04043 Phone: 207-985-7174 Fax: 207-985-1304 |
Dr. Kenneth D Warren Jr., DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 2 Berry Ct, Kennebunk, ME 04043 Phone: 207-985-9888 Fax: 207-985-3488 |
News Archive
McDavid 195 Ultralight Ankle Brace prevents acute injuries in amateur athletes
Lace-up ankle braces are designed to prevent acute ankle injury in amateur athletes. But until now, that statement wasn't backed up with any hard-core evidence. A recent study, the most extensive of its kind, shows that lace-up ankle braces, specifically the McDavid 195 Ultralight Ankle Brace, prevents most acute ankle injuries in amateur basketball players.
Chemical engineers devise new implantable tissue scaffold coated with bone growth factors
MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold induces the body to rapidly form new bone that looks and behaves just like the original tissue.
USPSTF releases draft recommendation on prostate cancer screening
Yesterday, the United States Preventive Services Task Force released a draft recommendation that states healthy men should no longer receive a P.S.A test for prostate cancer as it often leads to unnecessary testing and procedures and does not save lives.
Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference
Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.
› Verified 8 days ago
Occupational Therapists
Physical Therapists
Speech-Language Pathologists
Chiropractors
Podiatrists
Audiologists